<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337062</url>
  </required_header>
  <id_info>
    <org_study_id>DP10017</org_study_id>
    <nct_id>NCT02337062</nct_id>
  </id_info>
  <brief_title>Phase IIIb Study of APD421 in Combination as PONV Prophylaxis</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Combination Prophylaxis Against Post-operative Nausea and Vomiting in High-risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acacia Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acacia Pharma Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic
      in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting
      (PONV).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Response</measure>
    <time_frame>24 hours after the end of surgery</time_frame>
    <description>Complete response defined as no emesis and no use of rescue medication in the 24 hour period after end of surgery (defined as wound closure)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emesis</measure>
    <time_frame>24 hours after the end of surgery</time_frame>
    <description>Emesis is defined as vomiting (production of even the smallest amount of stomach contents) or retching (muscular movements of vomiting but without expulsion of stomach contents, usually because of an empty stomach)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Receiving Rescue Medication</measure>
    <time_frame>24 hours after the end of surgery</time_frame>
    <description>Rescue medication defined as an antiemetic (or other medication) given with the intention of relieving nausea and/or emesis, or any incidental use of a drug known to have antiemetic potential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Nausea</measure>
    <time_frame>24 hours after the end of surgery</time_frame>
    <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;Any nausea&quot; means a score ≥ 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Significant Nausea</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;Significant nausea&quot; means a score ≥ 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Violation of Criteria for PONV</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Criteria for PONV are any episode of emesis or use of rescue medication in the 24 hours after the end of surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1147</enrollment>
  <condition>PONV</condition>
  <arm_group>
    <arm_group_label>APD421 + standard anti-emetic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of IV APD421</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + standard anti-emetic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of IV placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD421</intervention_name>
    <arm_group_label>APD421 + standard anti-emetic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + standard anti-emetic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients ≥ 18 years of age

          -  Patients undergoing elective surgery (open or laparoscopic technique) under general
             anaesthesia, expected to last at least one hour from induction of anaesthesia to wound
             closure

          -  Patients with at least 3 &quot;Apfel&quot; risk factors for PONV

        Exclusion Criteria:

          -  Patients scheduled to undergo transplant surgery

          -  Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal
             or epidural) block

          -  Patients who are expected to remain ventilated for a period after surgery

          -  Patients who are expected to need a naso- or orogastric tube in situ after surgery is
             completed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Kranke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Würzburg University Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helen Keller Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF School of Medicine</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center Hospital</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Street Surgical Center</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victory Medical Center Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann-Memorial City Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68051</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Aue</name>
      <address>
        <city>Aue</city>
        <zip>08280</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps University</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 9, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <results_first_submitted>July 7, 2017</results_first_submitted>
  <results_first_submitted_qc>August 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 4, 2017</results_first_posted>
  <last_update_submitted>March 7, 2019</last_update_submitted>
  <last_update_submitted_qc>March 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study start date:- 12th February 2015 (first patient in)
Study completion date:- 28th September 2015 (last patient last visit)
Location:-France, Germany and the USA.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>APD421 + Standard Anti-emetic</title>
          <description>APD421 (amisulpride) at 5 mg administered as a single, slow, intravenous (IV) push over one minute at the time of induction of anaesthesia; given in combination with standard anti-emetic.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Standard Anti-emetic</title>
          <description>Matching Placebo administered as a single, slow push, IV push over one minute at the time of induction anaesthesia given in combination with standard anti-emetic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="572"/>
                <participants group_id="P2" count="575"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="555"/>
                <participants group_id="P2" count="556"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>APD421 + Standard Anti-emetic</title>
          <description>Single dose of IV APD421
APD421</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Standard Anti-emetic</title>
          <description>Single dose of IV placebo
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="572"/>
            <count group_id="B2" value="575"/>
            <count group_id="B3" value="1147"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="14.24"/>
                    <measurement group_id="B2" value="48.3" spread="13.98"/>
                    <measurement group_id="B3" value="48.5" spread="14.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="552"/>
                    <measurement group_id="B2" value="557"/>
                    <measurement group_id="B3" value="1109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="353"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Response</title>
        <description>Complete response defined as no emesis and no use of rescue medication in the 24 hour period after end of surgery (defined as wound closure)</description>
        <time_frame>24 hours after the end of surgery</time_frame>
        <population>Modified intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg + Standard Anti-emetic</title>
            <description>APD421 (amisulpride) at 5 mg administered as a single, slow, intravenous (IV) push over one minute at the time of induction of anaesthesia; given in combination with standard anti-emetic.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Standard Anti-emetic</title>
            <description>Matching placebo administered as a single, slow, IV push over one minute, at the time of induction of anaesthesia; given in combination with standard anti-emetic</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response</title>
          <description>Complete response defined as no emesis and no use of rescue medication in the 24 hour period after end of surgery (defined as wound closure)</description>
          <population>Modified intent-to-treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis was a comparison of the incidence of the primary efficacy variable between the two groups that received APD421 and the group that received placebo, using Pearson’s χ2 test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The threshold for determining statistical significance in the comparison of incidence of success between the active and placebo groups (the primary efficacy analysis) was a p-value of 2.5% one-sided.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emesis</title>
        <description>Emesis is defined as vomiting (production of even the smallest amount of stomach contents) or retching (muscular movements of vomiting but without expulsion of stomach contents, usually because of an empty stomach)</description>
        <time_frame>24 hours after the end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg + Standard Anti-emetic</title>
            <description>Single IV dose of 5 mg APD421 administered in combination with standard anti-emetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Standard Anti-emetic</title>
            <description>Single dose of IV placebo administered in combination with standard anti-emetic</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emesis</title>
          <description>Emesis is defined as vomiting (production of even the smallest amount of stomach contents) or retching (muscular movements of vomiting but without expulsion of stomach contents, usually because of an empty stomach)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Receiving Rescue Medication</title>
        <description>Rescue medication defined as an antiemetic (or other medication) given with the intention of relieving nausea and/or emesis, or any incidental use of a drug known to have antiemetic potential</description>
        <time_frame>24 hours after the end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg + Standard Anti-emetic</title>
            <description>Single IV dose of 5 mg APD421 administered in combination with standard anti-emetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Standard Anti-emetic</title>
            <description>Single dose of IV placebo administered in combination with standard anti-emetic</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Receiving Rescue Medication</title>
          <description>Rescue medication defined as an antiemetic (or other medication) given with the intention of relieving nausea and/or emesis, or any incidental use of a drug known to have antiemetic potential</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234"/>
                    <measurement group_id="O2" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Nausea</title>
        <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;Any nausea&quot; means a score ≥ 1.</description>
        <time_frame>24 hours after the end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg + Standard Anti-emetic</title>
            <description>Single IV dose of 5 mg APD421 administered in combination with standard anti-emetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Standard Anti-emetic</title>
            <description>Single dose of IV placebo administered in combination with standard anti-emetic</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Nausea</title>
          <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;Any nausea&quot; means a score ≥ 1.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286"/>
                    <measurement group_id="O2" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Significant Nausea</title>
        <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;Significant nausea&quot; means a score ≥ 4.</description>
        <time_frame>24 hours after end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg + Standard Anti-emetic</title>
            <description>Single IV dose of 5 mg APD421 administered in combination with standard anti-emetic</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Standard Anti-emetic</title>
            <description>Single dose of IV placebo administered in combination with standard anti-emetic</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Significant Nausea</title>
          <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;Significant nausea&quot; means a score ≥ 4.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Violation of Criteria for PONV</title>
        <description>Criteria for PONV are any episode of emesis or use of rescue medication in the 24 hours after the end of surgery</description>
        <time_frame>24 hours after end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 5mg + Standard Anti-emetic</title>
            <description>APD421 (amisulpride) at 5 mg administered as a single, slow, intravenous (IV) push over one minute at the time of induction of anaesthesia; given in combination with standard anti-emetic.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Standard Anti-emetic</title>
            <description>Matching placebo administered as a single, slow, IV push over one minute, at the time of induction of anaesthesia; given in combination with standard anti-emetic</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Violation of Criteria for PONV</title>
          <description>Criteria for PONV are any episode of emesis or use of rescue medication in the 24 hours after the end of surgery</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="575"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="195.5" upper_limit="NA">Median value not available as &lt;50% of participants met criteria for PONV. Upper bound of IQR not available as &lt;75% of participants met criteria for PONV.</measurement>
                    <measurement group_id="O2" value="821.0" lower_limit="107.0" upper_limit="NA">Upper bound of IQR not available as &lt;75% of participants met criteria for PONV.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the 7 day period after study drug administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>APD421 + Standard Anti-emetic</title>
          <description>Single dose of IV APD421
APD421</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Standard Anti-emetic</title>
          <description>Single dose of IV placebo
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="572"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="572"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="575"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="572"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="572"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="572"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="572"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="575"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="572"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="572"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Post Operative wound infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="572"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="572"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="572"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Staphylococcal infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="572"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="572"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="572"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="575"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="572"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Wound Secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="572"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Herpatic Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="572"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Pelvic Organ Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="572"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Postoerative ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="572"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Procedural Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="572"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="575"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="572"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="575"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="572"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="575"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="62" subjects_affected="62" subjects_at_risk="572"/>
                <counts group_id="E2" events="70" subjects_affected="70" subjects_at_risk="575"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="572"/>
                <counts group_id="E2" events="58" subjects_affected="58" subjects_at_risk="575"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations and caveats that occurred during the duration of this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Gabriel Fox</name_or_title>
      <organization>Acacia Pharma Ltd</organization>
      <phone>44-(0)1223-919764</phone>
      <email>GabrielFox@acaciapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

